Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Sucampo is focused on expanding Amitiza’s label and penetrating into new markets. Also, the company’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. The company has lowered its earnings outlook to include the Vtesee acquisition. Shares of the company have underperformed the industry.”

SCMP has been the subject of several other reports. Mizuho downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday. Maxim Group reaffirmed a “buy” rating and issued a $23.00 target price (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research report on Tuesday, August 8th. ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. BidaskClub lowered Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Roth Capital set a $30.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.14.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded down 8.506% during midday trading on Tuesday, hitting $11.025. The stock had a trading volume of 576,295 shares. The firm’s market cap is $510.73 million. Sucampo Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $17.55. The stock has a 50-day moving average price of $11.65 and a 200 day moving average price of $10.73.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. The firm had revenue of $59.90 million for the quarter, compared to analyst estimates of $56.44 million. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period last year, the company earned $0.24 EPS. On average, equities analysts anticipate that Sucampo Pharmaceuticals will post $1.02 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Raised to “Hold” at Zacks Investment Research” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/sucampo-pharmaceuticals-inc-scmp-raised-to-hold-at-zacks-investment-research/1605627.html.

In other Sucampo Pharmaceuticals news, insider Jones W. Bryan acquired 4,700 shares of the stock in a transaction on Friday, August 4th. The stock was purchased at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the purchase, the insider now directly owns 4,700 shares in the company, valued at $49,820. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Insiders own 4.13% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in SCMP. Great West Life Assurance Co. Can grew its position in shares of Sucampo Pharmaceuticals by 900.8% during the first quarter. Great West Life Assurance Co. Can now owns 35,778 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 32,203 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Sucampo Pharmaceuticals by 107.3% in the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 190,292 shares during the last quarter. Comerica Bank bought a new stake in shares of Sucampo Pharmaceuticals in the first quarter worth $275,000. Karp Capital Management Corp bought a new stake in shares of Sucampo Pharmaceuticals in the first quarter worth $119,000. Finally, Texas Permanent School Fund bought a new stake in shares of Sucampo Pharmaceuticals in the first quarter worth $197,000. Institutional investors own 55.44% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.